The purpose of this study is to investigate the effect of 500mcg roflumilast vs placebo on exacerbation rate and pulmonary function as well as quality of life in patients with chronic obstructive pulmonary disease (COPD).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
1,100
ALTANA Pharma
Cities in Australia, Australia
ALTANA Pharma
Cities in Austria, Austria
ALTANA Pharma
Cities in Canada, Canada
The frequency of patients experiencing at least one moderate or severe exacerbation during the treatment period.
Change in FEV1 from baseline during the treatment period.
Pulmonary function variables; quality of life variables;patient diary variables;safety
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
ALTANA Pharma
Cities in France, France
ALTANA Pharma
Cities in Hungary, Hungary
ALTANA Pharma
Cities in Italy, Italy
ALTANA Pharma
Cities in the Netherlands, Netherlands
ALTANA Pharma
Cities in Poland, Poland
ALTANA Pharma
Cities in Portugal, Portugal
ALTANA Pharma
Cities in the Russian Federation, Russia
...and 4 more locations